Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Sadasivan, Shankar ^a   Pond, Brooks B ^a,b   Pani, Amar K ^a   Qu, Chunxu ^a   Jiao, Yun ^a   Smeyne, Richard J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b EAST TENNESSEE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CATECHOLAMINE; METHYLPHENIDATE; CENTRAL STIMULANT AGENT; DOPAMINE TRANSPORTER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; INTERLEUKIN 6; SLC18A2 PROTEIN, MOUSE; SLC6A3 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA; VESICULAR MONOAMINE TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CELL ACTIVATION; CELL COUNT; CELL LOSS; CONTROLLED STUDY; DAT1 GENE; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; GDNF GENE; GENE; GENE EXPRESSION; IL 6 GENE; MICROGLIA; MORPHOLOGY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PROTEIN METABOLISM; SLC18A2 GENE; SLC6A3 GENE; STEREOLOGY; SUBSTANTIA NIGRA PARS COMPACTA; TNF ALPHA GENE; VMAT2 GENE; ANIMAL; CYTOLOGY; DNA MICROARRAY; DRUG EFFECT; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; SUBSTANTIA NIGRA;

MUS; PARKINSONIA;

ANIMALS; BASAL GANGLIA; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINERGIC NEURONS; GENE EXPRESSION PROFILING; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; INTERLEUKIN-6; METHYLPHENIDATE; MICE; MICROGLIA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SUBSTANTIA NIGRA; TUMOR NECROSIS FACTOR-ALPHA; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84858688253     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033693     Document Type: Article

References (70)

1. Arnsten AF, (2006) Stimulants: Therapeutic actions in ADHD. Neuropsychopharmacology 31: 2376-2383.
2. Capp PK, Pearl PL, Conlon C, (2005) Methylphenidate HCl: therapy for attention deficit hyperactivity disorder. Expert Rev Neurother 5: 325-331.
3. Hirai N, Nishino S, (2011) Recent advances in the treatment of narcolepsy. Curr Treat Options Neurol 13: 437-457.
4. Volkow ND, Wang GJ, Fowler JS, Fischman M, Foltin R, et al. (1999) Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sci 65: L7-12.
5. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE, (2011) Monitoring the Future national survey results on drug use, 1975-2010. pp. 1-312 Volume II: College students and adults ages 19-50. The University of Michigan.
6. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE, (2011) Monitoring the Future national survey results on drug use, 1975-2010. pp. 1-734 Volume I: Secondary school students. The University of Michigan.
7. Agay N, Yechiam E, Carmel Z, Levkovitz Y, (2010) Non-specific effects of methylphenidate (Ritalin) on cognitive ability and decision-making of ADHD and healthy adults. Psychopharmacology (Berl) 210: 511-519.
8. Camp-Bruno JA, Herting RL, (1994) Cognitive effects of milacemide and methylphenidate in healthy young adults. Psychopharmacology (Berl) 115: 46-52.
9. Repantis D, Schlattmann P, Laisney O, Heuser I, (2010) Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. Pharmacol Res 62: 187-206.
10. Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, et al. (2008) Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 456: 702-705.
11. Kimko HC, Cross JT, Abernethy DR, (1999) Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 37: 457-470.
12. Kuczenski R, Segal DS, (1997) Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 68: 2032-2037.
13. Schiffer WK, Volkow ND, Fowler JS, Alexoff DL, Logan J, et al. (2006) Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. Synapse 59: 243-251.
14. Reinoso BS, Undie AS, Levitt P, (1996) Dopamine receptors mediate differential morphological effects on cerebral cortical neurons in vitro. J Neurosci Res 43: 439-453.
15. Todd RD, (1992) Neural development is regulated by classical neurotransmitters: dopamine D2 receptor stimulation enhances neurite outgrowth. Biol Psychiatry 31: 794-807.
16. Filloux F, Townsend JJ, (1993) Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Experimental Neurology 119: 79-88.
17. Graham DG, (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14: 633-643.
18. Michel PP, Hefti F, (1990) Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. Journal Of Neuroscience Research 26: 428-435.
19. Asanuma M, Miyazaki I, Ogawa N, (2003) Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res 5: 165-176.
20. Baldwin HA, Colado MI, Murray TK, De Souza RJ, Green AR, (1993) Striatal dopamine release in vivo following neurotoxic doses of methamphetamine and effect of the neuroprotective drugs, chlormethiazole and dizocilpine. Br J Pharmacol 108: 590-596.
21. Gomes KM, Inacio CG, Valvassori SS, Reus GZ, Boeck CR, et al. (2009) Superoxide production after acute and chronic treatment with methylphenidate in young and adult rats. Neurosci Lett 465: 95-98.
22. Miyazaki I, Asanuma M, Hozumi H, Miyoshi K, Sogawa N, (2007) Protective effects of metallothionein against dopamine quinone-induced dopaminergic neurotoxicity. FEBS Lett 581: 5003-5008.
23. Miyazaki I, Asanuma M, (2008) Dopaminergic neuron-specific oxidative stress caused by dopamine itself. Acta Med Okayama 62: 141-150.
24. Jang H, Boltz D, McClaren J, Pani AK, Smeyne M, et al. (2012) Inflammatory effects of highly pathogenic H5N1 influenza virus infection in the CNS of mice. J Neurosci In Press.
25. Wargin W, Patrick K, Kilts C, Gualtieri CT, Ellington K, et al. (1983) Pharmacokinetics of methylphenidate in man, rat and monkey. J Pharmacol Exp Ther 226: 382-386.
26. Gerasimov MR, Franceschi M, Volkow ND, Rice O, Schiffer WK, et al. (2000) Synergistic interactions between nicotine and cocaine or methylphenidate depend on the dose of dopamine transporter inhibitor. Synapse 38: 432-437.
27. Valvassori SS, Frey BN, Martins MR, Reus GZ, Schimidtz F, et al. (2007) Sensitization and cross-sensitization after chronic treatment with methylphenidate in adolescent Wistar rats. Behav Pharmacol 18: 205-212.
28. Hamre K, Tharp R, Poon K, Xiong X, Smeyne RJ, (1999) Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus. Brain Res 828: 91-103.
29. Boyd JD, Jang H, Shepherd KR, Faherty C, Slack S, et al. (2007) Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta. Brain Res 1175: 107-116.
30. Leonard BE, McCartan D, White J, King DJ, (2004) Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol 19: 151-180.
31. Pawluk LK, Hurwitz TD, Schluter JL, Ullevig C, Mahowald MW, (1995) Psychiatric morbidity in narcoleptics on chronic high dose methylphenidate therapy. J Nerv Ment Dis 183: 45-48.
32. Evans WN, Morrill MS, Parente ST, (2010) Measuring inappropriate medical diagnosis and treatment in survey data: The case of ADHD among school-age children. J Health Econ 29: 657-673.
33. Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, et al. (2008) Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 47: 21-31.
34. Andersen SL, (2002) Changes in the second messenger cyclic AMP during development may underlie motoric symptoms in attention deficit/hyperactivity disorder (ADHD). Behav Brain Res 130: 197-201.
35. Gatley SJ, Volkow ND, Gifford AN, Fowler JS, Dewey SL, et al. (1999) Dopamine-transporter occupancy after intravenous doses of cocaine and methylphenidate in mice and humans. Psychopharmacology (Berl) 146: 93-100.
36. Volkow ND, Wang GJ, Fowler JS, Logan J, Franceschi D, et al. (2002) Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse 43: 181-187.
37. Koda K, Ago Y, Cong Y, Kita Y, Takuma K, et al. (2010) Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. J Neurochem 114: 259-270.
38. Shen XM, Zhang F, Dryhurst G, (1997) Oxidation of dopamine in the presence of cysteine: characterization of new toxic products. Chem Res Toxicol 10: 147-155.
39. Choi HJ, Kim SW, Lee SY, Hwang O, (2003) Dopamine-dependent cytotoxicity of tetrahydrobiopterin: a possible mechanism for selective neurodegeneration in Parkinson's disease. J Neurochem 86: 143-152.
40. Choi HJ, Lee SY, Cho Y, Hwang O, (2005) Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease. Neurochem Int 46: 329-335.
41. Whitehead RE, Ferrer JV, Javitch JA, Justice JB, (2001) Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. J Neurochem 76: 1242-1251.
42. Lloyd SA, Faherty CJ, Smeyne RJ, (2006) Adult and in utero exposure to cocaine alters sensitivity to the Parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 137: 905-913.
43. Gomes KM, Petronilho FC, Mantovani M, Garbelotto T, Boeck CR, et al. (2008) Antioxidant enzyme activities following acute or chronic methylphenidate treatment in young rats. Neurochem Res 33: 1024-1027.
44. Martins MR, Reinke A, Petronilho FC, Gomes KM, Dal-Pizzol F, et al. (2006) Methylphenidate treatment induces oxidative stress in young rat brain. Brain Res 1078: 189-197.
45. Carvey PM, Punati A, Newman MB, (2006) Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis. Cell Transplant 15: 239-250.
46. Cory-Slechta DA, Thiruchelvam M, Barlow BK, Richfield EK, (2005) Developmental pesticide models of the Parkinson disease phenotype. Environ Health Perspect 113: 1263-1270.
47. Weidong L, Shen C, Jankovic J, (2009) Etiopathogenesis of Parkinson disease: a new beginning? Neuroscientist 15: 28-35.
48. Jackson-Lewis V, Smeyne RJ, (2005) MPTP and SNpc DA neuronal vulnerability: role of dopamine, superoxide and nitric oxide in neurotoxicity. Minireview. Neurotox Res 7: 193-202.
49. Yokoyama H, Kuroiwa H, Yano R, Araki T, (2008) Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson's disease. Neurol Sci 29: 293-301.
50. Przedborski S, Ischiropoulos H, (2005) Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease. Antioxid Redox Signal 7: 685-693.
51. Callaghan RC, Cunningham JK, Sykes J, Kish SJ, (2012) Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend 120: 35-40.
52. Fumagalli F, Gainetdinov RR, Wang YM, Valenzano KJ, Miller GW, et al. (1999) Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J Neurosci 19: 2424-2431.
53. Uhl GR, Li S, Takahashi N, Itokawa K, Lin Z, et al. (2000) The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins. Faseb J 14: 2459-2465.
54. Kuhn DM, Aretha CW, Geddes TJ, (1999) Peroxynitrite inactivation of tyrosine hydroxylase: mediation by sulfhydryl oxidation, not tyrosine nitration. J Neurosci 19: 10289-10294.
55. Xu Y, Stokes AH, Roskoski R Jr, Vrana KE, (1998) Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. J Neurosci Res 54: 691-697.
56. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, et al. (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46: 598-605.
57. Barlow BK, Cory-Slechta DA, Richfield EK, Thiruchelvam M, (2007) The gestational environment and Parkinson's disease: evidence for neurodevelopmental origins of a neurodegenerative disorder. Reprod Toxicol 23: 457-470.
58. Callaghan RC, Cunningham JK, Sajeev G, Kish SJ, (2010) Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders. Mov Disord 25: 2333-2339.
59. Walitza S, Melfsen S, Herhaus G, Scheuerpflug P, Warnke A, et al. (2007) Association of Parkinson's disease with symptoms of attention deficit hyperactivity disorder in childhood. J Neural Transm Suppl pp. 311-315.
60. Croche AF, Lipman RS, Overall JE, Hung W, (1979) The effects of stimulant medication on the growth of hyperkinetic children. Pediatrics 63: 847-850.
61. Martins S, Tramontina S, Polanczyk G, Eizirik M, Swanson JM, et al. (2004) Weekend holidays during methylphenidate use in ADHD children: a randomized clinical trial. J Child Adolesc Psychopharmacol 14: 195-206.
62. Swanson JM, Volkow ND, (2002) Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD. Behav Brain Res 130: 73-78.
63. Paxinos G, Franklin KBJ, (2001) The Mouse Brain in Stereotaxic Coordinates San Diego Academic Press.
64. Baquet ZC, Williams D, Brody J, Smeyne RJ, (2009) A comparison of model-based (2D) and design-based (3D) stereological methods for estimating cell number in the substantia nigra pars compacta (SNpc) of the C57BL/6J Mouse. Neuroscience 161: 1082-1090.
65. West MJ, Slomianka L, Gundersen HJ, (1991) Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231: 482-497.
66. Graeber MB, Streit WJ, (2010) Microglia: biology and pathology. Acta Neuropathol 119: 89-105.
67. Graeber MB, (2010) Changing face of microglia. Science 330: 783-788.
68. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
69. Johnson WE, Li C, Rabinovic A, (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8: 118-127.
70. Smyth GK, (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.